320 related articles for article (PubMed ID: 28280336)
1. Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer.
Liang Y; Tian B; Zhang J; Li K; Wang L; Han J; Wu Z
Int J Nanomedicine; 2017; 12():1699-1715. PubMed ID: 28280336
[TBL] [Abstract][Full Text] [Related]
2. A NAG-Guided Nano-Delivery System for Redox- and pH-Triggered Intracellularly Sequential Drug Release in Cancer Cells.
Liang Y; Zhang J; Tian B; Wu Z; Svirskis D; Han J
Int J Nanomedicine; 2020; 15():841-855. PubMed ID: 32103941
[TBL] [Abstract][Full Text] [Related]
3. Synergistic combination therapy of lung cancer: Cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-Demethylnobiletin.
Guo S; Zhang Y; Wu Z; Zhang L; He D; Li X; Wang Z
Biomed Pharmacother; 2019 Oct; 118():109225. PubMed ID: 31325705
[TBL] [Abstract][Full Text] [Related]
4. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
5. Lymph cancer chemotherapy: delivery of doxorubicin-gemcitabine prodrug and vincristine by nanostructured lipid carriers.
Ni S; Qiu L; Zhang G; Zhou H; Han Y
Int J Nanomedicine; 2017; 12():1565-1576. PubMed ID: 28280326
[TBL] [Abstract][Full Text] [Related]
6. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect.
Wang Y; Zhang H; Hao J; Li B; Li M; Xiuwen W
Drug Deliv; 2016 May; 23(4):1398-403. PubMed ID: 26079530
[TBL] [Abstract][Full Text] [Related]
7. Surface-engineered nanostructured lipid carrier systems for synergistic combination oncotherapy of non-small cell lung cancer.
Rawal S; Bora V; Patel B; Patel M
Drug Deliv Transl Res; 2021 Oct; 11(5):2030-2051. PubMed ID: 33215254
[TBL] [Abstract][Full Text] [Related]
8. Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells.
Zhou J; Sun M; Jin S; Fan L; Zhu W; Sui X; Cao L; Yang C; Han C
Drug Deliv; 2019 Dec; 26(1):281-289. PubMed ID: 30880491
[TBL] [Abstract][Full Text] [Related]
9. High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy.
Sun J; Chen Y; Xu J; Song X; Wan Z; Du Y; Ma W; Li X; Zhang L; Li S
Theranostics; 2020; 10(3):1136-1150. PubMed ID: 31938056
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment.
Larson N; Yang J; Ray A; Cheney DL; Ghandehari H; Kopeček J
Int J Pharm; 2013 Sep; 454(1):435-43. PubMed ID: 23827653
[TBL] [Abstract][Full Text] [Related]
11. Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box-Behnken design.
Emami J; Rezazadeh M; Sadeghi H; Khadivar K
Pharm Dev Technol; 2017 May; 22(3):370-382. PubMed ID: 27689412
[TBL] [Abstract][Full Text] [Related]
12. RIPL peptide-conjugated nanostructured lipid carriers for enhanced intracellular drug delivery to hepsin-expressing cancer cells.
Lee SG; Kim CH; Sung SW; Lee ES; Goh MS; Yoon HY; Kang MJ; Lee S; Choi YW
Int J Nanomedicine; 2018; 13():3263-3278. PubMed ID: 29910614
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy.
Lu Z; Su J; Li Z; Zhan Y; Ye D
Drug Dev Ind Pharm; 2017 Jan; 43(1):160-170. PubMed ID: 27553814
[TBL] [Abstract][Full Text] [Related]
14. Synergistic activity of combination therapy with PEGylated pemetrexed and gemcitabine for an effective cancer treatment.
Vandana M; Sahoo SK
Eur J Pharm Biopharm; 2015 Aug; 94():83-93. PubMed ID: 25968494
[TBL] [Abstract][Full Text] [Related]
15. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.
Shao Z; Shao J; Tan B; Guan S; Liu Z; Zhao Z; He F; Zhao J
Int J Nanomedicine; 2015; 10():1223-33. PubMed ID: 25709444
[TBL] [Abstract][Full Text] [Related]
16. A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity.
Jian Y; Zhao M; Cao J; Fan T; Bu W; Yang Y; Li W; Zhang W; Qiao Y; Wang J; Wen A
Drug Des Devel Ther; 2020; 14():2355-2370. PubMed ID: 32606603
[TBL] [Abstract][Full Text] [Related]
17. Targeted Nanostructured Lipid Carriers for Delivery of Paclitaxel to Cancer Cells: Preparation, Characterization, and Cell Toxicity.
Rezazadeh M; Emami J; Hassanzadeh F; Sadeghi H; Rostami M; Mohammadkhani H
Curr Drug Deliv; 2017; 14(8):1189-1200. PubMed ID: 28472908
[TBL] [Abstract][Full Text] [Related]
18. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery.
Wu M; Fan Y; Lv S; Xiao B; Ye M; Zhu X
Drug Deliv; 2016 Oct; 23(8):2720-2725. PubMed ID: 26203691
[TBL] [Abstract][Full Text] [Related]
19. Nanocarrier-Based Combination Chemotherapy for Resistant Tumor: Development, Characterization, and Ex Vivo Cytotoxicity Assessment.
Raikwar S; Vyas S; Sharma R; Mody N; Dubey S; Vyas SP
AAPS PharmSciTech; 2018 Nov; 19(8):3839-3849. PubMed ID: 30280350
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein-Inspired Nanocarrier Composed of Folic Acid-Modified Protein and Lipids: Preparation and Evaluation of Tumor-Targeting Effect.
Han M; Ji X; Li J; Ge Z; Luo B; Zhou K; Wang Q; Sun X; Zhang W; Li J
Int J Nanomedicine; 2020; 15():3433-3445. PubMed ID: 32523342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
